logo.png
Bioxytran Peer-Reviewed Journal in “Vaccines” Contains Mechanism Capable of Targeting Future COVID-19 Mutations
June 27, 2023 07:00 ET | BIOXYTRAN, INC.
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)Complete elimination of most symptoms by day 7Galectin antagonist acts as an entry inhibitor for use in...
logo.png
Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment
June 12, 2023 09:00 ET | BIOXYTRAN, INC.
- Funding in place to meet next regulatory milestone BOSTON, MASSACHUSETTS, June 12, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company...
logo.png
Bioxytran Interview at the Emerging Growth Conference
May 01, 2023 08:00 ET | BIOXYTRAN, INC.
Wednesday, May 3, 2023 12:35 pm –1:05 pm ESTMedical/Scientific Community Reaction to Peer Reviewed Article BOSTON, MASSACHUSETTS, May 01, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT)...
logo.png
Bioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials
April 19, 2023 09:00 ET | BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, April 19, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral...
logo.png
Bioxytran Interview at the Emerging Growth Conference
April 03, 2023 15:04 ET | BIOXYTRAN, INC.
Wednesday, April 5, 2023 10:50 am –11:20am ESTDiscussion of Peer Reviewed Article and Long COVID BOSTON, MASSACHUSETTS, April 03, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the...
logo.png
Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal
March 29, 2023 07:00 ET | BIOXYTRAN, INC.
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)Complete elimination of most symptoms by day 7 Galectin antagonist acts as an entry inhibitor for use in...
logo.png
ProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial Virus
February 28, 2023 08:00 ET | BIOXYTRAN, INC.
Activity in Influenza and Respiratory Syncytial Virus highlights the broad- spectrum antiviral potential of ProLectin-M BOSTON, MASSACHUSETTS, Feb. 28, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC....
logo.png
Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug
February 22, 2023 08:00 ET | BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat...
logo.png
Bioxytran to Appear on ClearThink IR’s Virtual Live Event
February 14, 2023 09:00 ET | BIOXYTRAN, INC.
 - Wednesday, February 15th, 2023 12:00 EST  - Virtual Fireside Chat via Paltalk Platform BOSTON, MASSACHUSETTS, Feb. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”),...
logo.png
Bioxytran Receives Approval to Initiate Trials with ProLectin-I
February 06, 2023 09:00 ET | BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Feb. 06, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19...